Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 7028Session 2025

What changed between versions

8 paragraphs changed+9 words added−13 removed

Highlighted text was added in the newer version. Struck-through text was removed.

Florida Senate

-

2025

(Proposed Bill) SPBSB 7028

FOR CONSIDERATION By

By

the Committee on Health Policy

588-02667A-25 20257028pb588-02849-25 20257028__

1 A bill to be entitled

251 unchanged paragraphs

2 An act relating to cancer; amending s. 381.915, F.S.;

3 revising the definitions of the terms “cancer center”

4 and “Florida-based”; defining the term “Cancer Connect

5 Collaborative” or “collaborative”; making clarifying

6 changes; deleting an obsolete date; revising the

7 composition of the collaborative; deleting obsolete

8 provisions; requiring the collaborative to review all

9 submitted Cancer Innovation Fund grant applications

10 using certain parameters; requiring the collaborative

11 to give priority to certain applications; requiring

12 licensed or certified health care providers,

13 facilities, or entities to meet certain criteria to be

14 eligible for specified grant funding; specifying such

15 criteria; requiring the Department of Health to

16 appoint peer review panels for a specified purpose;

17 requiring that priority scores be forwarded to the

18 collaborative and be considered in determining which

19 proposals the collaborative recommends for certain

20 grant funding; requiring the collaborative and peer

21 review panels to establish and follow certain

22 guidelines and adhere to a certain policy; prohibiting

23 a member of the collaborative or a panel from

24 participating in certain discussions or decisions

25 under certain circumstances; requiring, beginning on a

26 specified date and annually thereafter, the

27 collaborative to prepare and submit a specified report

28 to the Governor and the Legislature; requiring that

29 the report include certain information; revising the

30 requirements for a specified report by the department;

31 requiring, beginning on a specified date, that certain

32 allocation agreements include certain information;

33 providing legislative findings; creating the Cancer

34 Connect Collaborative Research Incubator within the

35 department, and overseen by the collaborative, to

36 provide funding for a specified purpose over a

37 specified timeframe; specifying the incubator’s

38 targeted area of cancer research for the first

39 specified timeframe; providing that grants issued

40 through the incubator are contingent upon the

41 appropriation of funds and must be awarded through a

42 specified process; requiring that priority be given to

43 certain applicants; authorizing the prioritization of

44 certain grant proposals; providing that applications

45 for incubator funding may be submitted by specified

46 hospitals; requiring that all qualified applicants

47 have equal access and opportunity to compete for

48 research funding; requiring that incubator grants be

49 recommended by the collaborative and awarded by the

50 department in a certain manner; requiring the

51 department to appoint peer review panels for a

52 specified purpose; requiring that priority scores be

53 forwarded to the collaborative and be considered in

54 determining which proposals the collaborative

55 recommends for funding; requiring the collaborative

56 and peer review panels to establish and follow certain

57 guidelines and adhere to a certain policy; prohibiting

58 a member of the collaborative or a panel from

59 participating in certain discussions or decisions;

60 requiring recipients of incubator grant funds to enter

61 into an allocation agreement with the department;

62 specifying requirements for such allocation

63 agreements; requiring, beginning on a specified date

64 and annually until a specified date, the collaborative

65 to prepare and submit a specified report to the

66 Governor and the Legislature; requiring the

67 collaborative to make a certain recommendation under

68 certain circumstances; requiring that a specified

69 report include certain information; amending s.

70 381.922, F.S.; establishing the Bascom Palmer Eye

71 Institute VisionGen Initiative within the William G.

72 “Bill” Bankhead, Jr., and David Coley Cancer Research

73 Program; providing the purpose of the initiative;

74 providing that funding for the initiative is subject

75 to annual appropriation; providing an effective date.

76

77 Be It Enacted by the Legislature of the State of Florida:

78

79 Section 1. Present paragraphs (c), (d), and (e) of

80 subsection (3) and present subsections (12) and (13) of section

81 381.915, Florida Statutes, are redesignated as paragraphs (d),

82 (e), and (f) of subsection (3) and subsections (13) and (14),

83 respectively, a new paragraph (c) is added to subsection (3),

84 paragraph (d) is added to subsection (10), a new subsection (12)

85 is added to that section, and paragraph (b) and present

86 paragraph (c) of subsection (3), paragraphs (a), (b), (e), (f),

87 and (h) of subsection (8), and subsections (9) and (11) of that

88 section are amended, to read:

89 381.915 Casey DeSantis Cancer Research Program.—

90 (3) On or before September 15 of each year, the department

91 shall calculate an allocation fraction to be used for

92 distributing funds to participating cancer centers. On or before

93 the final business day of each quarter of the state fiscal year,

94 the department shall distribute to each participating cancer

95 center one-fourth of that cancer center’s annual allocation

96 calculated under subsection (6). The allocation fraction for

97 each participating cancer center is based on the cancer center’s

98 tier-designated weight under subsection (4) multiplied by each

99 of the following allocation factors based on activities in this

100 state: number of reportable cases, peer-review costs, and

101 biomedical education and training. As used in this section, the

102 term:

103 (b) “Cancer center” means a comprehensive center with at

104 least one geographic site in the state, a freestanding center

105 located in the state, a center situated within an academic

106 institution, or a Florida-based formal research-based consortium

107 under centralized leadership that has achieved NCI designation

108

or is prepared to achieve NCI designation by June 30, 2024

.

109

(c) “Cancer Connect Collaborative

” or “collaborative

” means

110

the council created under s

ubs

ection (8).

111

(d)

(c)

“Florida-based” means that a cancer center’s actual

112 or sought designated status is or would be recognized by the NCI

113 as primarily located in Florida and not in another state

, or

114

that a health care provider or facility is physically located in

115

Florida and provides services in Florida

.

116 (8) The Cancer Connect Collaborative, a council as defined

117 in s. 20.03, is created within the department to advise the

118 department and the Legislature on developing a holistic approach

119 to the state’s efforts to fund cancer research, cancer

120 facilities, and treatments for cancer patients. The

121 collaborative may make recommendations on proposed legislation,

122 proposed rules, best practices, data collection and reporting,

123 issuance of grant funds, and other proposals for state policy

124 relating to cancer research or treatment.

125 (a) The Surgeon General shall serve as an ex officio,

126 nonvoting member

of the collaborative

and shall serve as the

127 chair.

128 (b) The collaborative shall be composed of the following

129 voting members

, to be appointed by September 1, 2024

:

130 1. Two members appointed by the Governor,

t

hree

members

one

131

member

appointed by the President of the Senate, and

t

hree

132

members

one member

appointed by the Speaker of the House of

133 Representatives, based on the criteria of this subparagraph. The

134 appointing officers shall make their appointments prioritizing

135 members who have the following experience or expertise:

136 a. The practice of a health care profession specializing in

137 oncology clinical care or research;

138 b. The development of preventive and therapeutic treatments

139 to control cancer;

140 c. The development of innovative research into the causes

141 of cancer, the development of effective treatments for persons

142 with cancer, or cures for cancer; or

143 d. Management-level experience with a cancer center

144 licensed under chapter 395.

145 2. One member who is a resident of this state who can

146 represent the interests of cancer patients in this state,

147 appointed by the Governor.

148 (e) Members

of the collaborative

whose terms have expired

149 may continue to serve until replaced or reappointed, but for no

150 more than 6 months after the expiration of their terms.

151 (f) Members

of the collaborative

shall serve without

152 compensation but are entitled to reimbursement for per diem and

153 travel expenses pursuant to s. 112.061.

154

(h)

The collaborative shall develop a long-range

155

comprehensive plan for the Casey DeSantis Cancer Research

156

Program. In the development of the plan, the collaborative must

157

solicit input from cancer centers, research institutions,

158

biomedical education institutions, hospitals, and medical

159

providers. The collaborative shall submit the plan to the

160

Governor, the President of the Senate, and the Speaker of the

161

House of Representatives no later than December 1, 2024. The

162

plan must include, but need not be limited to, all of the

163

following components:

164

1. Expansion of grant fund opportunities to include a

165

broader pool of Florida-based cancer centers, research

166

institutions, biomedical education institutions, hospitals, and

167

medical providers to receive funding through the Cancer

168

Innovation Fund.

169

2. An evaluation to determine metrics that focus on patient

170

outcomes, quality of care, and efficacy of treatment.

171

3. A compilation of best practices relating to cancer

172

research or treatment

.

173 (9)

(a)

The collaborative shall advise the department on the

174 awarding of grants issued through the Cancer Innovation Fund.

175 During any fiscal year for which funds are appropriated to the

176 fund, the collaborative shall review all submitted grant

177 applications

using the parameters provided in

paragraph (

c

)

and

178 make recommendations to the department for awarding grants to

179 support innovative cancer research and treatment models,

180 including emerging research and treatment trends and promising

181 treatments that may serve as catalysts for further research and

182 treatments. The department shall make the final grant allocation

183 awards. The collaborative shall give priority to applications

184 seeking to expand the reach of

cancer screening efforts and

185 innovative cancer treatment models into underserved areas of

186 this state.

187

(

b

)

To be eligible for grant funding under this sectionsubsection, a

188

a

licensed or certified health care provider, facility, or entity

189

entity

must

631 unchanged paragraphs

meet

at least one of

the following criteria

:

190

1

. Operate

s

as

a licensed hospital that has a minimum of 30

191

percent

of

its

current cancer patients

residing

in rural or

192

underserved areas

.

193

2

. Operate

s

as

a licensed health care clinic or facility

194

that employs or contracts with at least one physician

licensed

195

under chapter 458 or chapter 459

who

is board certified

in

196

oncology and that

administers

chemotherapy treatments for

197

cancer

.

198

3

. Operate

s

as

a licensed facility that employs or

199

contracts with at least one

physician licensed under chapter 458

200

or chapter 459 who is board

certified in oncology

and that

201

administers

radiation therapy treatments for cancer

.

202

4.

Operate

s

as

a licensed health care clinic or facility

203

that provides cancer screening services at no cost or a minimal

204

cost to patients.

205

5

. Operate

s

as a rural hospital as defined in s.

206

395.602(2)(b)

.

207

6

. Operate

s

as a critical access hospital as defined in s.

208

408.07(14)

.

209

7

. Operate

s

as a specialty hospital as defined in s.

210

395.002(28)(a)

which

provides cancer treatment for

patients

from

211

birth to

18 years

of age.

212

8

. Engage

s

in biomedical research intended to develop

213

therapies, medical pharmaceuticals, treatment protocols, or

214

medical procedures intended to cure cancer or improve the

215

quality of life of cancer patients

.

216

9

. Educate

s

or train

s

students, postdoctoral fellows, or

217

licensed or certified health care practitioners in the

218

screening, diagnosis, or treatment of cancer.

219

(

c

) To ensure that all proposals for

grant funding

issued

220

through the Cancer Innovation Fund are appropriate and are

221

evaluated fairly on the basis of scientific merit, the

222

department shall appoint peer review panels of independent,

223

scientifically qualified individuals to review the scientific

224

merit of each proposal and establish its priority score. The

225

priority scores

must

be forwarded to the collaborative and must

226

be considered in determining which proposals the collaborative

227

recommends

for grant funding through the

Cancer Innovation Fund.

228

(

d

) The collaborative and the peer review panels shall

229

establish and follow rigorous guidelines for ethical conduct and

230

adhere to a strict policy with regard to conflicts of interest

231

regarding the assessment of Cancer Innovation Fund grant

232

applications. A member of the collaborative or a panel may not

233

participate in any discussion or decision of the collaborative

234

or a panel with respect to a research proposal by any firm,

235

entity, or agency with which the member is associated as a

236

member of the governing body or as an employee or with which the

237

member has entered into a contractual arrangement.

238

(

e

)

Beginning December 1, 2025, and annually thereafter,

239

t

he collaborative shall

prepare and submit

a report to the

240

Governor,

the

President of the Senate, and

the

Speaker of the

241

House of Representative

s

which

identifies and evaluates

the

242

performance and

the impact

of

grants issued through

the

Cancer

243

Innovation Fund

on cancer treatment,

research,

screening,

244

diagnosis, prevention, practitioner

training,

workforce

245

education, and

cancer patient

survivorship. The report

must

246

include

all of

the following:

247

1

. Amounts of grant funds awarded to each

recipient

.

248

2

. Descriptions of each

recipien

t’s research or project

249

which

include

, but need not be limited to,

the following:

250

a.

Goals or projected outcomes

.

251

b.

Population to be served

.

252

c.

Research methods or project implementation plan

.

253

3

.

An assessment of

grant recipients

which

evaluates

their

254

p

rogress

toward achieving objectives specified in

each

255

recipient’s

grant application.

256

4

.

Recommendations for best practices

that may

be

257

implemented by health care providers in

this state

who

diagnose,

258

treat, and screen for cancer

, based on the outcomes of projects

259

funded through the Cancer Innovation Fund

.

260 (10) Beginning July 1, 2025, and each year thereafter, the

261 department, in conjunction with participating cancer centers,

262 shall submit a report to the Cancer Control and Research

263 Advisory Council and the collaborative on specific metrics

264 relating to cancer mortality and external funding for cancer

265 related research in this state. If a cancer center does not

266 endorse this report or produce an equivalent independent report,

267 the cancer center is ineligible to receive program funding for 1

268 year. The department must submit this annual report, and any

269 equivalent independent reports, to the Governor, the President

270 of the Senate, and the Speaker of the House of Representatives

271 no later than September 15 of each year the report or reports

272 are submitted by the department. The report must include:

273

(d) A description of the numbers and types of cancer cases

274

treated

annually at each participating cancer center

, including

275

reportable and nonreportable cases

.

276 (11) Beginning July 1,

2025

2024

, each allocation agreement

277 issued by the department relating to cancer center payments

278 under

paragraph (2)(a)

subsection (2)

must include all of the

279 following:

280 (a) A line-item budget narrative documenting the annual

281 allocation of funds to a cancer center.

282 (b) A cap on the annual award of 15 percent for

283 administrative expenses.

284 (c) A requirement for the cancer center to submit quarterly

285 reports of all expenditures made by the cancer center with funds

286 received through the Casey DeSantis Cancer Research Program.

287 (d) A provision to allow the department and other state

288 auditing bodies to audit all financial records, supporting

289 documents, statistical records, and any other documents

290 pertinent to the allocation agreement.

291 (e) A provision requiring the annual reporting of outcome

292 data and protocols used in achieving those outcomes.

293

(12)(a)

The Legislature finds that targeted areas of cancer

294

research require increased resources and that Florida should

295

become a leader in promoting research opportunities for these

296

targeted areas. Floridians should not have to leave the state to

297

receive the most advanced cancer care and treatment. To meet

298

this need, the Cancer Connect Collaborative Research Incubator

,

299

or “incubator” as used in this subsection,

is created within the

300

department, to be overseen by the collaborative, to provide

301

funding for a targeted area of cancer research

over

a

5

-year

302

period. For the

5

-year period beginning July 1, 2025, the

303

i

ncubator’s targeted area of cancer research

is

pediatric

304

cancer.

305

(b)

Contingent

up

on the appropriation of funds by the

306

Legislature, grants issued through the

i

ncubator

must

be awarded

307

through a peer-reviewed, competitive process.

Priority

must

be

308

given to applicants that focus on

enhancing

both research and

309

treatment

by increasing

participation in clinical trials

related

310

to the targeted area of cancer research, including

all of the

311

following

:

312

1. Identifying

strategies

to increase enrollment in cancer

313

clinical trials

.

314

2. Supporting public and private professional education

315

programs

to raise

awareness and knowledge about cancer clinical

316

trials

.

317

3. Providing tools

for

cancer patients and community-based

318

oncologists to

help identify available cancer clinical trials i

n

319

th

is

state

.

320

4. Creating opportunities for the state’s academic cancer

321

centers to collaborate with community-based oncologists in

322

cancer clinical trial

networks.

323

(c)

Priority

may be given to grant proposals that foster

324

collaborations among institutions, researchers, and community

325

practitioners to support the advancement of cures through basic

326

or applied research, including clinical trials involving cancer

327

patients and related networks.

328

(d) Applications for

i

ncubator funding may be submitted by

329

any Florida-based specialty hospital as defined in s.

330

395.002(28)(a)

which

provides cancer treatment for patients from

331

birth to 18 years

of age

. All qualified applicants

must

have

332

equal access and opportunity to compete for research funding.

333

Incubator grants

must

be recommended by the collaborative and

334

awarded by the department on the basis of scientific merit, as

335

determined by a competitively open and peer-reviewed process to

336

ensure objectivity, consistency, and high quality.

337

(e) To ensure that all proposals for research funding are

338

appropriate and are evaluated fairly on the basis of scientific

339

merit, the department shall appoint peer review panels of

340

independent, scientifically qualified individuals to review the

341

scientific merit of each proposal and establish its priority

342

score. The priority scores

must

be forwarded to the

343

collaborative and must be considered in determining which

344

proposals the collaborative recommends for funding.

345

(f) The collaborative and the peer review panels shall

346

establish and follow rigorous guidelines for ethical conduct and

347

adhere to a strict policy with regard to conflicts of interest

348

regarding the assessment of incubator grant applications

. A

349

member of the collaborative or a panel may not participate in

350

any discussion or decision of the collaborative or a panel

351

regarding

a research proposal

from

any firm, entity, or agency

352

with which the member is associated

as a governing body member,

353

as an employee, or through

a contractual arrangement.

354

(g) Each recipient of

i

ncubator grant funds must enter into

355

an allocation agreement with the department. Each such

356

allocation agreement must include all of the following:

357

1. A line-item budget narrative documenting the annual

358

allocation of funds to a recipient.

359

2. A cap on the annual award of 15 percent for

360

administrative expenses.

361

3. A requirement for the recipient to submit quarterly

362

reports of all expenditures made by the recipient with funds

363

received through the

incubator.

364

4. A provision to allow the department and other state

365

auditing bodies to audit all financial records, supporting

366

documents, statistical records, and any other documents

367

pertinent to the allocation agreement.

368

5. A provision requiring the annual reporting of outcome

369

data and protocols used in achieving those outcomes.

370

(h) Beginning December 1, 2026, and annually through

371

December 1, 2030, the collaborative shall

prepare and

submit a

372

report to the Governor,

the

President of the Senate, and

the

373

Speaker of the House of Representatives

which

evaluates research

374

conducted through the

i

ncubator and provides details on outcomes

375

and findings available through the end of the fiscal year

376

immediately preceding each report. If the collaborative

377

recommend

s

that the

i

ncubator be extended beyond its

5

-year

378

lifespan, the collaborative shall make such recommendation in

379

the report due December 1, 2029, and shall include a

380

recommendation for the next targeted area of cancer research.

381

The report due on December 1, 2030, must include

all of the

382

following

:

383

1.

Details of all results of the research conducted with

384

i

ncubator funding

which

has been completed or the status of

385

research in progress.

386

2.

An evaluation of all research conducted with

i

ncubator

387

funding during the

5

fiscal years preceding the report.

388 Section 2. Paragraph (d) is added to subsection (2) of

389 section 381.922, Florida Statutes, to read:

390 381.922 William G. “Bill” Bankhead, Jr., and David Coley

391 Cancer Research Program.—

392 (2) The program shall provide grants for cancer research to

393 further the search for cures for cancer.

394

(d) There is established within the program the

Bascom

395

Palmer Eye Institute

VisionGen

Initiative. The purpose of the

396

initiative is to advance

genetic and epigenetic research on

397

inherited eye diseases and ocular oncology

by awarding grants

398

through the peer-reviewed, competitive process established under

399

subsection (3).

Funding for the initiative

is subject to the

400

annual appropriation of funds by the Legislature.

401 Section 3. This act shall take effect July 1, 2025.

Back to the full text